Aktienanalyse zu CytoMed Therapeutics Ltd (GDTC)GDTCCytoMed Therapeutics Ltd

CytoMed Therapeutics Limited is a biopharmaceutical company. It is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The Company also has the allogeneic gamma delta T cell technology, namely TCB-002. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

CytoMed Therapeutics Ltd (GDTC) is not a good buy right now due to its poor financial performance and negative momentum indicators. The current price is $0.86, with a 52-week high of $2.29, indicating a significant drop of 62.4%. Additionally, the RSI is at 31.414, suggesting that the stock is oversold, but this does not guarantee a rebound. The gross margin has improved to 87.51%, but the company continues to report negative net income, with a loss of -885,226 SGD in the latest quarter. The main risk is the declining stock price, which has dropped 56.4% over the past year, indicating ongoing challenges for the company.